Amphastar Earnings Call Balances Growth and Margin Strain
Amphastar Pharmaceuticals Inc ((AMPH)) has held its Q1 earnings call. Read on for the main highlights of the call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Amphastar Pharmaceuticals struck a cautious tone this quarter, balancing modest top-line growth with clear earnings pressure. Management highlighted resilient demand, strong cash generation and progress on new products, yet acknowledged sharp profit declines driven by pricing pressure, product mix shifts and higher operating costs, leaving investors weighing long-term upside against near-term margin compression.
Net Revenue Stabilization and Cash Flow Strength
Amphastar reported Q1 2026 net revenues of $171.2 million, edging past last year’s $170.5 million and marking a return to growth despite pricing challenges. Operating cash flow reached roughly $47.8 million, and management reaffirmed 2026 corporate unit sales guidance calling for mid- to high-single-digit percentage growth.
BAQSIMI Volume Growth Under Pricing Pressure
BAQSIMI posted about $32.4 million in revenue as U.S. unit volumes climbed roughly 8% year over year, underscoring healthy underlying demand. To combat margin erosion from higher rebates and discounts, the company enacted a 3% list price increase on May 1 and hired an outside firm to address potential duplicate 340B rebate payments.
Primatene MIST Maintains Steady Momentum
Primatene MIST revenue rose around 2% to $29.8 million, supported by approximately 6.5% growth in store-level sales versus last year. Management credited sustained consumer demand and ongoing commercial investment, positioning this over-the-counter asthma product as a stable contributor in an otherwise mixed portfolio.
New Launches and Portfolio Expansion Drive Growth
The April launch of AMP-007, the first and only generic inhaled ipratropium on the market, was highlighted as Amphastar’s top near-term growth driver. Alongside other recent introductions, it helped lift other finished pharmaceutical product sales by 34% to $67.1 million, with notable gains from albuterol, teriparatide and iron sucrose.
Advancing a Higher-Value Late-Stage Pipeline
Management emphasized progress on late-stage programs, including an insulin aspart biosimilar and a GLP-1 ANDA both targeted for commercial launch in 2027. The company is also pushing forward early-stage proprietary oncology and immunology assets, with plans for future IND filings and a corticotropin program aiming for Phase I around 2027.
Balance Sheet Flexibility and Share Repurchases
The company underscored a strong financial position that supports continued R&D investment and selective deals in M&A or licensing. Reflecting confidence in its outlook and balance sheet, Amphastar completed $29.5 million of accelerated share repurchases in the quarter, retiring roughly 3% of its share count.
BAQSIMI Revenue Decline from Rebate and 340B Pressure
Despite solid volume trends, BAQSIMI revenue fell about 15% from $38.4 million to $32.4 million as higher rebates and increased 340B pharmacy discounts dragged down average selling prices. Management reset expectations, now guiding BAQSIMI sales to be flat to up low-single digits in 2026 as pricing actions and rebate controls gradually take hold.
Severe Glucagon Sales Decline Amid Competition
Glucagon injection revenue plunged roughly 56% to $9.2 million from $20.8 million, reflecting intensified competition and a market shift toward ready-to-use formulations. Executives cautioned that glucagon sales are likely to decline further, though they expect the rate of erosion to slow from here.
Earnings and Margin Compression Weigh on Results
Net income slid to $6.4 million, or $0.14 per share, compared with $25.3 million, or $0.51 per share, in the prior-year quarter, while adjusted net income halved to $19.5 million, or $0.42 per share. Cost of revenues climbed to $100.8 million from $85.3 million, as lower BAQSIMI prices, weaker sales of higher-margin products and higher facility costs combined to squeeze profitability.
Rising Operating Expenses Pressure Profitability
Research and development spending jumped about 33% to $26.7 million, including a $2 million upfront payment tied to an in-licensing deal, reflecting the company’s push into higher-value programs. General and administrative costs rose around 13% to $18.0 million, driven by legal, staffing and ERP implementation expenses that are depressing near-term earnings.
Legacy Product Pricing and Competitive Headwinds
Management cited growing pricing variability and competitive pressure across several legacy products, adding another layer of near-term volatility. Amphastar is responding with tighter rebate management, revised contracting and selective list price changes, though the company acknowledged that these measures will take time to offset current headwinds.
Forward-Looking Guidance and 2027 Pipeline Horizon
Looking ahead to 2026, Amphastar maintained its outlook for mid- to high-single-digit unit growth while trimming BAQSIMI expectations to flat-to-low-single-digit revenue gains and implementing a modest list price hike. Management pointed investors toward AMP-007’s recent launch and the planned 2027 commercialization of insulin aspart and GLP-1 products as key pillars of the company’s longer-term growth story.
Amphastar’s latest call painted a story of a business in transition, with resilient demand and a deepening pipeline offset by short-term earnings strain and competitive friction. For investors, the trade-off is clear: near-term margin pressure in exchange for a strengthened product mix and potential higher-value growth as new launches and late-stage assets move toward market.
